We further used a panel (constructed by CRISPR/Cas9 genome editing), comprising p53-wild-type, p53-null, and p53-GOF mutant cells, to demonstrate that the anti-tumor effect of FTD occurred independently of p53 status. This evidence concerns the gene TP53 and neoplasm.